Synonyms: Bosulif® | SK 606 | SK-606 | SKI 606
bosutinib is an approved drug (FDA (2012), EMA (2013))
Compound class:
Synthetic organic
Comment: Bosutinib is a Type-1 kinase inhibitor. This compound is a dual inhibitor of Src family kinases and Abl kinase activity [8].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖![]() View more information in the IUPHAR Pharmacology Education Project: bosutinib |
|
Immunopharmacology Comments |
Bosutinib is reported as a pan-salt inducible kinase (SIK) inhibitor [7]. Bosutinib-induced inhibition of SIK2 has anti-inflammatory action, mediated via induction of a macrophage phentoype switch to a 'regulatory'-like phenotype [7]. These 'regulatory'-like macrophages produce the anti-inflammatory cytokine IL-10 and promote the resolution of inflammation. Inhibition of SIK2 to promote macrophage switch to a 'regulatory'-like phenotype is considered a potential therapeutic strategy for the treatment of chronic inflammatory diseases. |